The letter is in regards to certain disclosures made by the company on the ongoing US FDA audit of companys unit-1 and observations made by the US FDA between the period 2019 to 2022. The SEBI warning letter observes that the company had disclosed very limited and restricted information and that the company did not disclose the detailed reasons and also did not consider-the observations of US FDA as serious. The company has been advised to ensure compliance with all applicable provisions of SEBI Regulations and to place this warning letter before its board of directors in ensuing board meeting. Aurobindo Pharma develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. The companys consolidated net profit declined 28.1% to Rs 576.46 crore on a 3.3% fall in net sales to Rs 5,795.34 crore in Q4 FY22 over Q4 FY21. The scrip shed 0.42% to currently trade at Rs 524.20 on the BSE. Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.